Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib

doi:10.4251/wjgo.v8.i7.555

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9372)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

447

WORD

316

HTML

3371

Figures (1-2)

159

Tables (1-4)

149

Sum=4442

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

543

Download

1204

Sum=1747

Publishing Process of This Article

Item

Count

Browse

1084

Download

2099

Sum=3183

Jul 15, 2016 (publication date) through Apr 23, 2024

Times Cited of This Article

Times Cited (28)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Jul 15, 2016; 8(7): 555-562
Published online Jul 15, 2016. doi: 10.4251/wjgo.v8.i7.555

Full Size Figure Download Figure

Figure 1 Kaplan-Meier curves for progression-free survival and overall survival according to the neutrophil-lymphocyte ratio. A: PFS stratified according to the NLR; B: Overall survival stratified according to the NLR. NLR: Neutrophil-to-lymphocyte ratio; PFS: Progression-free survival.

Citation: Lee JM, Lee HS, Hyun JJ, Choi HS, Kim ES, Keum B, Seo YS, Jeen YT, Chun HJ, Um SH, Kim CD. Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib. World J Gastrointest Oncol 2016; 8(7): 555-562
URL: https://www.wjgnet.com/1948-5204/full/v8/i7/555.htm
DOI: https://dx.doi.org/10.4251/wjgo.v8.i7.555